Komal Padhariya, Richie Bhandare*, Daniel Canney and Vinay Velingkar Pages 86 - 104 ( 19 )
Background: The serotonin 2B receptor subtype (5-HT2BR), located in central nervous system (CNS), cardiovascular system (CVS) and the gastrointestinal tract (GIT), is an important target for the treatment of migraine, obesity and irritable bowel syndrome. 5-HT2BR is necessary for the myocardial cell proliferation and differentiation at the embroyonic stage for healthy development of heart. Recently, its involvement in drug induced valvulopathy and other myocardial disorders, have paved a way for selective antagonist for the treatment of cardiac disorders.
Conclusion: The current review summarizes the limited progress made in the past decade for design and development of 5-HT2BR antagonists for the treatment of disorders related to heart. We focus primarily on the different scaffolds reported in both manuscripts and patents, that have led to selectivity for 5-HT2B over subtype 5-HT2A/2C. Opportunities in cardiovascular drug development for novel 5-HT2BR antagonists are also presented.
Serotonin inhibitors, 5-HT2BR antagonist, valvulopathy, pulmonary arterial hypertension, tryptophan platelet, platelet aggregation.
Department of Pharmaceutical Chemistry, SPP School of Pharmacy and Technology Management, SVKM's NMIMS University, V.L Mehta Road, Vile Parle (West), Mumbai 400056, Department of Pharmaceutical Chemistry & Pharmacognosy, College of Pharmacy & Health Sciences, Ajman University, Ajman, Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, Philadelphia, PA-19122, Department of Quality Assurance, SPP School of Pharmacy and Technology Management, SVKM's NMIMS University, V.L Mehta Road, Vile Parle (West), Mumbai 400056